MKI67 and neoplasm: Further molecular analysis of residual orthotopic and heterotopic tumor tissues treated with the drug revealed decreased Ki67 levels and STAT3 signaling, as well as a decrease in MES phenotypes, which reveals the therapeutic potential of pioglitazone in vitro and in vivo (Fig. 4b, c, e).